|
|
|
|
|||||
|
|
|
Chicago, IL – September 2, 2025 – Stocks in this week’s article are Post Holdings POST, Pediatrix Medical Group, Inc. MD, Envista NVST and Zions Bancorporation ZION.
Stocks hitting their 52-week high and delivering consistent performance offer attractive opportunities to investors while building a portfolio. This is because stocks near that level are perceived to be winners. However, stocks touching a new 52-week high are often predisposed to profit-taking, resulting in pullbacks and trend reversals.
Moreover, given the high price, investors often wonder if the stock is overpriced. While the speculations are not absolutely baseless, all stocks hitting a 52-week high are not necessarily overpriced.
In fact, investors might lose out on top gainers in an attempt to avoid the steep prices.
Stocks such as Post Holdings, Pediatrix Medical Group, Inc., Envista and Zions Bancorporation are expected to maintain their momentum and keep scaling new highs. Extensive information on a stock is necessary to understand whether or not there is scope for further upside.
Here, we discuss a strategy to find the right stocks. The strategy borrows from the basics of momentum investing. This technique bets on “buy high, sell higher.”
Many times, stocks that hit a 52-week high fail to scale higher despite having potential. This is because investors fear that the stocks are overvalued and expect the price to crash.
In fact, overvaluation is natural for most of these stocks as investors’ focus (or willingness to pay a premium) has helped them reach the level. But that does not always indicate an impending decline. Factors such as robust sales, surging profit levels, earnings growth prospects and strategic acquisitions that encourage investors to bet on these stocks could keep them motivated if there is no tangible negative. In other words, the momentum might continue.
Also, when a string of positive developments dominates the market, investors find their underreaction unwarranted, even if there are no company-specific driving forces.
Here are four stocks, each sporting a Zacks Rank #1, out of the 24 that made it through the screen:
Post Holdings continues to expand through strategic acquisitions, including the purchase of Potato Products of Idaho, marking its entry into the refrigerated and frozen potato market. The Foodservice segment emerged as a key growth driver in the second quarter of fiscal 2025, with a 9.6% increase in sales, fueled by value-added egg products and ready-to-drink shakes.
Strategic pricing actions in Weetabix and Refrigerated Retail helped offset cost pressure and are expected to support results going forward. The planned acquisition of 8th Avenue Food & Provisions further strengthened the company’s portfolio and led to an upward revision in the adjusted EBITDA guidance. Supported by solid cash flows, Post Holdings returned capital to shareholders through share repurchases, reflecting confidence in its outlook and long-term strategy.
The Zacks Consensus Estimate for POST’s fiscal 2025 earnings has moved north by 3.3% to $6.95 per share in the past 30 days. The company surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 21.43%.
Pediatrix Medical Group has stepped up its commitment to shareholder returns with a new $250 million share repurchase authorization, underpinned by solid cash generation. Over the past 12 months, the company produced $245 million in operating cash flow, marking an 18.4% year-over-year increase.
Profitability has risen, thanks to the divestiture of lower-margin, non-core assets, allowing the company to concentrate on its core physician services. Return on capital now stands at 10.6%, comfortably above the industry average of 7.4%. Operational momentum is also evident.
Higher patient volumes, improved acuity, favorable collections and reduced operating expenses are lifting performance. Management now expects 2025 adjusted EBITDA in the range of $245-$255 million compared with its earlier projection of $220-$240 million.
The Zacks Consensus Estimate for MD’s 2025 earnings has moved north by 9.3% to $1.73 per share in the past 30 days. The company surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 28.74%.
Envista is a global family of more than 30 dental brands, including Nobel Biocare, Ormco, DEXIS and Kerr, built through the acquisition and integration of over 25 leading dental businesses. Envista is making progress in its three core focus areas. The Spark business is consistently taking shares and expanding gross margins.
Amid ongoing macro uncertainty, the company is driving strong contributions from EBS. New acquisitions continue to capture strong synergies. Furthermore, the company’s growing international presence is supported by its trusted brands, innovative product offerings and comprehensive customer service. A stable global dental market creates a favorable long-term growth opportunity for the company. Solid financial stability also bodes well for the stock.
The Zacks Consensus Estimate for NVST’s 2025 earnings has moved north by 7.7% to $1.12 per share in the past 30 days. The company surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 16.5%.
Zions Bancorporation is a diversified financial service provider, operating a widespread network of more than 400 branches. Zions has been opportunistically repurchasing shares. In February, the company approved a plan authorizing the buyback of up to $40 million worth of shares for 2025, which was completed in the first quarter.
The company intends to repurchase shares cautiously until it has further regulatory clarity on capital norms. As of June 30, 2025, Zions’ common equity tier 1 capital ratio was 11%, up from 10.6% in the prior-year period. Zions’ solid balance sheet and robust liquidity continue to underpin its financial stability and enhance shareholder value. The company holds long-term issuer ratings of BBB+ from both Standard & Poor's and Fitch Ratings, and Baa2 from Moody’s Investors Service.
The Zacks Consensus Estimate for ZION’s 2025 earnings has moved north by 1.9% to $5.78 per share in the past 30 days. The company surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 12.1%.
Get the rest of the stocks on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and back-testing software.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your trial to the Research Wizard today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial to the Research Wizard today.
For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2744741/4-stocks-trading-near-52-week-high-with-room-to-rise-further
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://www.twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Email: [email protected]
Visit: https://www.zacks.com/
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).
| Sep-02 | |
| Sep-02 | |
| Sep-02 | |
| Sep-02 | |
| Sep-02 | |
| Sep-02 | |
| Sep-02 | |
| Sep-01 | |
| Sep-01 | |
| Sep-01 | |
| Sep-01 | |
| Sep-01 | |
| Sep-01 | |
| Aug-30 | |
| Aug-29 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite